CRISPR Stock Buy Hold or Sell Recommendation

CRSP
 Stock
  

USD 63.79  3.02  4.97%   

Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding CRISPR Therapeutics AG is 'Buy'. Macroaxis provides CRISPR Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CRSP positions. The advice algorithm takes into account all of CRISPR Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
  
Refresh
The advice is provided from CRISPR Therapeutics' buy-and-hold perspective. Continue to CRISPR Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as CRISPR and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards CRISPR Therapeutics AG.

Execute CRISPR Therapeutics Buy or Sell Advice

The CRISPR recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on CRISPR Therapeutics AG. Macroaxis does not own or have any residual interests in CRISPR Therapeutics AG or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute CRISPR Therapeutics' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell CRISPR TherapeuticsBuy CRISPR Therapeutics
Buy

Volatility

Very steadyDetails

Hype Condition

Low keyDetails

Current Valuation

UndervaluedDetails

Odds of Distress

Very LowDetails

Economic Sensitivity

Actively responds to the marketDetails

Analyst Consensus

BuyDetails

Financial Strenth (F Score)

HealthyDetails

Financial Leverage

InapplicableDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon CRISPR Therapeutics AG has a Risk Adjusted Performance of 0.0324, Jensen Alpha of 0.4158, Total Risk Alpha of 0.8186, Sortino Ratio of 0.0515 and Treynor Ratio of 0.0497
Macroaxis provides unbiased investment recommendation on CRISPR Therapeutics that should be used to complement current analysts and expert consensus on CRISPR Therapeutics AG. Our trade advice engine determines the company's potential to grow exclusively from the perspective of an investors' current risk tolerance and investing horizon. To make sure CRISPR Therapeutics is not overpriced, please confirm all CRISPR Therapeutics fundamentals, including its total debt, market capitalization, and the relationship between the gross profit and short ratio . Given that CRISPR Therapeutics has a number of shares shorted of 10.14 M, we suggest you to validate CRISPR Therapeutics AG market performance and probability of bankruptcy to ensure the company can sustain itself for few more years given your prevailing risk tolerance and investing horizon.

CRISPR Therapeutics Trading Alerts and Improvement Suggestions

CRISPR Therapeutics has very high historical volatility over the last 90 days
CRISPR Therapeutics is unlikely to experience financial distress in the next 2 years
About 63.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.benzinga.com: Statistics on Global CRISPR Genome Editing Market Size Share to Surpass USD 15.84 Billion by 2028, Exhi - Benzinga

CRISPR Therapeutics current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CRISPR analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CRISPR analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Mean Price121.86
Target Median Price117.00
Target High Price220.00
Recommendation Mean2.20
Number Of Analyst Opinions22
Target Low Price52.00
Average Consensus Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

CRISPR Therapeutics Returns Distribution Density

The distribution of CRISPR Therapeutics' historical returns is an attempt to chart the future uncertainty of CRISPR Therapeutics' future price movements. The chart of the probability distribution of CRISPR Therapeutics stock daily returns describes the distribution of returns around its average expected value. We use CRISPR Therapeutics AG price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of CRISPR Therapeutics returns is essential to provide solid investment advice for CRISPR Therapeutics stock.
Mean Return0.1Value At Risk-7.81
Potential Upside8.29Standard Deviation5.43
 Return Density 
      Distribution 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of CRISPR Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

CRISPR Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as CRISPR Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CRISPR Therapeutics AG backward and forwards among themselves. CRISPR Therapeutics' institutional investor refers to the entity that pools money to purchase CRISPR Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Ark Investment Management LlcCommon Shares9.4 M590.3 M
Nea Management Company LlcCommon Shares1.6 M365.6 M
Nikko Asset Management Americas IncCommon Shares4.6 M291 M
Sumitomo Mitsui Trust Holdings IncCommon Shares4.6 M290 M
Capital International InvestorsCommon Shares3.6 M226.1 M
Blackrock IncCommon Shares2.3 M143 M
Loomis Sayles Co L PCommon Shares1.3 M81 M
Note, although CRISPR Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

CRISPR Therapeutics Cash Flow Accounts

201720182019202020212022 (projected)
Capital Expenditure(7.81 M)(2.77 M)(6.68 M)(18.36 M)(81.7 M)(83.86 M)
Depreciation Amortization and Accretion3.02 M3.52 M4.72 M9.18 M17.95 M19.37 M
Net Cash Flow or Change in Cash and Cash Equivalents(75.76 M)216.9 M489 M236.66 M(245.52 M)(251.99 M)
Issuance Purchase of Equity Shares2.61 M315.93 M430.98 M1.02 B250.94 M284.48 M
Net Cash Flow from Financing2.61 M315.93 M430.98 M1.02 B250.94 M298.65 M
Net Cash Flow from Investing(8.31 M)(2.77 M)1.32 M(541.17 M)(1.04 B)(1.06 B)
Net Cash Flow from Operations(70.09 M)(96.24 M)56.68 M(238.37 M)538.97 M581.52 M
Effect of Exchange Rate Changes on Cash41 K(22 K)15 K40 K(11 K)(11.29 K)
Share Based Compensation18.87 M34.98 M44.06 M66.02 M102.39 M110.47 M

CRISPR Therapeutics Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to CRISPR Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that CRISPR Therapeutics stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a CRISPR stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over DOW
0.42
β
Beta against DOW1.72
σ
Overall volatility
5.46
Ir
Information ratio 0.05

CRISPR Therapeutics Volatility Alert

CRISPR Therapeutics AG exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate CRISPR Therapeutics AG individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about CRISPR Therapeutics future systematic risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure CRISPR Therapeutics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact CRISPR Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

CRISPR Therapeutics Implied Volatility

CRISPR Therapeutics' implied volatility exposes the market's sentiment of CRISPR Therapeutics AG stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if CRISPR Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that CRISPR Therapeutics stock will not fluctuate a lot when CRISPR Therapeutics' options are near their expiration.

CRISPR Therapeutics Fundamentals Vs Peers

Comparing CRISPR Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze CRISPR Therapeutics' direct or indirect competition across all of the common fundamentals between CRISPR Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as CRISPR Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of CRISPR Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing CRISPR Therapeutics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare CRISPR Therapeutics to competition
FundamentalsCRISPR TherapeuticsPeer Average
Return On Equity18.59 %(0.31) %
Return On Asset10.19 %(0.14) %
Profit Margin41.28 %(1.27) %
Operating Margin40.82 %(5.51) %
Current Valuation1.67 B16.62 B
Shares Outstanding76.53 M571.82 M
Shares Owned by Insiders1.48 %10.09 %
Shares Owned by Institutions62.57 %39.21 %
Number of Shares Shorted10.14 M4.71 M
Price to Earning12.12 X28.72 X
Price to Book1.94 X9.51 X
Price to Sales5.34 X11.42 X
Revenue914.96 M9.43 B
Gross Profit476.33 M27.38 B
EBITDA391.48 M3.9 B
Net Income377.66 M570.98 M
Cash and Equivalents2.38 B2.7 B
Cash per Share30.87 X5.01 X
Total Debt225.03 M5.32 B
Debt to Equity0.09 %48.70 %
Current Ratio20.17 X2.16 X
Book Value Per Share32.86 X1.93 K
Cash Flow from Operations538.97 M971.22 M
Short Ratio9.06 X4.00 X
Earnings Per Share5.26 X3.12 X
Price to Earnings To Growth0.03 X4.89 X
Number of Employees47318.84 K
Beta2.01-0.15
Market Capitalization4.88 B19.03 B
Total Asset279 M29.47 B
Retained Earnings(230.62 M)9.33 B
Working Capital154 M1.48 B
Current Asset232 M9.34 B
   Exercise or conversion by Samarth Kulkarni of 25000 shares of CRISPR Therapeutics subject to Rule 16b-3 [view details]

About CRISPR Therapeutics Buy or Sell Advice

When is the right time to buy or sell CRISPR Therapeutics AG? Buying financial instruments such as CRISPR Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Although CRISPR Therapeutics investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2019 2020 2021 2022 (projected)
Current Assets987.55 M1.72 B2.42 B2.61 B
Total Assets1.07 B1.83 B2.75 B2.97 B

Use Investing Ideas to Build Portfolios

In addition to having CRISPR Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Oil And Gas Thematic Idea Now

Oil And Gas
Oil And Gas Theme
Companies involved in drilling, production, and distribution of oil and gas pipelines. The Oil And Gas theme has 20 constituents.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Oil And Gas Theme or any other thematic opportunities.
View All  Next Launch Oil And Gas
Continue to CRISPR Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.9 B
Quarterly Revenue Growth YOY
0.74
Return On Assets
0.0855
Return On Equity
0.15
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.